On March 2nd, the donation ceremony of Frost & Sullivanx's Disease Challenge Foundation was successfully held in Shanghai. Dr. Wang Xin, Global Partner and President of Frost & Sullivan Greater China, Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, Wang Yigou, Founder and Vice Chairman of the Disease Challenge Foundation, and Ma Tao, Secretary-General of the Disease Challenge Foundation, along with their respective teams, attended the donation ceremony.
At the donation ceremony, Dr. Wang Xin, on behalf of Frost & Sullivan (referred to as 'Frost & Sullivan'), donated 100,000 RMB to the Beijing Disease Challenge Public Welfare Foundation (referred to as 'Disease Challenge Foundation', abbreviated as 'ICF') to jointly promote the prevention and treatment of rare diseases in China and light up the lives of patients with rare diseases.
As a globally renowned growth consulting company, Frost & Sullivan has always been committed to growth and giving back to society over the past sixty years. Therefore, Frost & Sullivan has always regarded engaging in public welfare as an important part of its social responsibility.
Dr. Wang Xin, Global Partner and President of Frost & Sullivan Greater China, said: 'Frost & Sullivan's corporate mission is to make the world a better place through growth. Corporate growth and social responsibility complement each other and are both our foundation for existence. Since last year, Frost & Sullivan has started cooperation with the Disease Challenge Foundation, providing public with industry observation reports on rare diseases and returning the research income from these reports to the foundation to serve with knowledge, doing our best to help more patients with rare diseases. We also hope that this can help capital markets and investment institutions, as well as more enterprises and individuals, understand and pay attention to the field of rare diseases and this special group. Paying attention to the rare disease group is a responsibility of the whole society. This is a very meaningful thing, and it is also a research topic that our company attaches great importance to and will invest in for a long time.'
Wang Yigou, Founder and Vice Chairman of the Disease Challenge Foundation, said: 'The mission of ICF is to focus on patients, empower them, innovate, and connect relevant parties to jointly solve the urgent problems faced by the rare disease group. As a public welfare platform in the field of rare diseases, ICF has been jointly writing industry trend observation reports on rare diseases with Frost & Sullivan for two years. We hope that through the action, thinking, and observation insights of the foundation serving patients on the front line, combined with Frost & Sullivan's professional ability in industry analysis, we can jointly record and present changes in the field of rare diseases. In the future, ICF hopes to continue working hand in hand with Frost & Sullivan to jointly solve the urgent problems faced by the rare disease group and also provide more valuable industry reports for partners from all walks of life who are committed to improving the living conditions of the rare disease group.'
In the process of jointly releasing the '2023 China Rare Disease Industry Trend Observation Report' this year, the experts of the foundation provided comprehensive guidance for report writing. Frost & Sullivan hopes that both sides can work together to build each year's rare disease industry observation report into a high-level 'anniversary volume' of the rare disease industry, using their influence and platform resources to speak out for rare diseases.
In the future, Frost & Sullivan sincerely looks forward to paying attention to and jointly ensuring with all sectors of society to strive for helping the rare disease group have colorful lives. Frost & Sullivan will contribute to the development and maturity of China's rare disease industry through its rich industry experience, maintain long-term and in-depth cooperation with institutions such as the Disease Challenge Foundation; continue to be committed to research in the field of rare diseases, actively practice its social responsibility, and continuously contribute to the construction of 'Healthy China 2030'.
